Dr. Ari M. Melnick on Biomarkers in Lymphoma

Ari M. Melnick, MD
Published: Thursday, Apr 11, 2013

Ari M. Melnick, MD, Professor of Medicine, Weill Cornell Medical College, comments on biomarkers in lymphoma.

Studies of epigenetic regulation in lymphomas are identifying clinically-useful biomarkers and revealing biological insights into how lymphomas function. Lymphomas exhibit a great degree of epigenetic heterogeneity, which is an indicator of disease aggressiveness and increases the populations of cells that can survive chemotherapy and repopulate the disease.

Cytosine methylation patterns in lymphoma are reversible. The potential remains to inhibit DNA methyltransferases and overcome the negative effects of epigenetic heterogeneity.

Ari M. Melnick, MD, Professor of Medicine, Weill Cornell Medical College, comments on biomarkers in lymphoma.

Studies of epigenetic regulation in lymphomas are identifying clinically-useful biomarkers and revealing biological insights into how lymphomas function. Lymphomas exhibit a great degree of epigenetic heterogeneity, which is an indicator of disease aggressiveness and increases the populations of cells that can survive chemotherapy and repopulate the disease.

Cytosine methylation patterns in lymphoma are reversible. The potential remains to inhibit DNA methyltransferases and overcome the negative effects of epigenetic heterogeneity.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Hematology Briefings™: Advancing Care and Improving Outcomes for Patients With Pyruvate Kinase DeficiencyOct 31, 20181.0
Publication Bottom Border
Border Publication
x